Brachytherapy offers excellent oncologic outcomes and is associated with a low rate of adverse events, data show.
Pedro J. Prada, MD, of Hospital Universitario Central de Asturias, Oviedo, Spain, and collaborators looked at PSA relapse-free survival and adverse effects in 734 patients who had 125iodine brachytherapy for localized prostate cancer. The median follow-up was 55 months and the maximum follow-up was 10 years. Of the 734 patients, 26 (3.5%) suffered a PSA relapse, 11 (1.5%) died from prostate cancer, and 20 (2.7%) died from other causes.
The 10-year actuarial biochemical control was 92%, 84%, and 65% for patients with low-, intermediate-, and high-risk prostate cancer, respectively, according to findings published in BJU International (2010; published online ahead of print).
In addition, the 10-year actuarial biochemical control according to Gleason score was 88%, 76%, and 67% for patients with Gleason scores of 6 or less, 7, and greater than 7, respectively. The 10-year actuarial biochemical control was 90%, 80%, and 42% for men with preoperative PSA levels of 10 or less, 10.1-20, and greater than 20 ng/mL. No patients reported incontinence following treatment. Twenty-two patients (2.9%) experienced acute urinary retention.